Mesoblast (MESO) Gross Margin (2016 - 2023)
Mesoblast recorded quarterly Gross Margin of 254.46% in Q2 2023, up 95.94% quarter-over-quarter from 6265.65% in Q1 2023, and up 14195.0% year-over-year from N/an in Q2 2022.
Mesoblast's Gross Margin history runs 8 years deep, the most recent figure standing at 254.46% for Q2 2023.
- In Q2 2023, Gross Margin rose 14195.0% year-over-year to 254.46%; the TTM figure through Mar 2023 stood at 6153.24% (down 656189.0% YoY), while the FY2025 annual figure was 70.17%, changed N/A from the prior year.
- Gross Margin came in at 254.46% for Q2 2023 at Mesoblast, up from 6265.65% in the prior quarter.
- In the past five years, Gross Margin ranged from a high of 17116.73% in Q2 2021 to a low of 17383.92% in Q3 2022.
- A 5-year average of 2456.05% and a median of 1787.92% in 2019 frame the typical range for Gross Margin.
- Across the five-year window, Gross Margin jumped 1625798 bps in 2021 and tumbled 1751314 bps in 2022, its largest moves.
- Mesoblast's Gross Margin stood at 4284.76% in 2019, then jumped by 96 bps to 187.82% in 2020, then slumped by 3953 bps to 7612.85% in 2021, then jumped by 43 bps to 4324.65% in 2022, then soared by 94 bps to 254.46% in 2023.
- According to Business Quant data, Gross Margin over the past three periods registered 254.46%, 6265.65%, and 4324.65% for Q2 2023, Q1 2023, and Q4 2022 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 79.04% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 86.85% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 91.79% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 82.22% |
| 10 | Mesoblast | 23.40 Bn | 23.27 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | -254.46% |
| Mar 31, 2023 | -6,265.65% |
| Dec 31, 2022 | -4,324.65% |
| Sep 30, 2022 | -17,383.92% |
| Jun 30, 2022 | -396.40% |
| Mar 31, 2022 | -177.97% |
| Dec 31, 2021 | -7,612.85% |
| Sep 30, 2021 | -4,984.60% |
| Jun 30, 2021 | 17,116.73% |
| Mar 31, 2021 | -267.62% |
| Dec 31, 2020 | -187.82% |
| Sep 30, 2020 | -813.72% |
| Jun 30, 2020 | 858.76% |
| Mar 31, 2020 | -3,957.95% |
| Dec 31, 2019 | -4,284.76% |
| Sep 30, 2019 | -2,762.13% |
| Jun 30, 2019 | -24.45% |
| Mar 31, 2019 | -8,485.41% |
| Dec 31, 2018 | -7,347.17% |
| Sep 30, 2018 | -6,322.17% |
| Jun 30, 2018 | -24.76% |
| Mar 31, 2018 | -9,612.01% |
| Dec 31, 2017 | -2,643.58% |
| Sep 30, 2017 | 25.30% |
| Jun 30, 2017 | -103.18% |
| Mar 31, 2017 | -325.08% |
| Dec 31, 2016 | -775.29% |
| Sep 30, 2016 | -1,411.47% |
| Jun 30, 2016 | 71.27% |
| Mar 31, 2016 | -100.55% |